The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

被引：0
|
作者：
Yu, Guopan [1 ]
Yao, Zurong [1 ]
Yin, Zhao [1 ]
Zhang, Yu [1 ]
Zhao, Weihua [2 ]
Weng, Guangyang [3 ]
Guo, Ziwen [4 ]
Sun, Zhiqiang [5 ]
Shi, Pengcheng [1 ]
Jiang, Xuejie [6 ]
Xu, Dan [1 ]
Xuan, Li [1 ]
Liu, Qifa [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Dept Hematol, Nanning, Peoples R China
[3] Shenzhen Second Peoples Hosp, Dept Hematol, Shenzhen, Peoples R China
[4] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[5] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 2, Dept Hematol, Guangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
homoharringtonine; venetoclax/azacitidine; acute myeloid leukemia; efficacy; safety;
D O I：
10.1182/blood-2024-206872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4283 / 4283
页数：1
相关论文
共 50 条
  • [21] Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An OpenLabel, Multi-Center Study
    Wen, Ziyu
    Zhao, Ying
    Li, Guowei
    Su, YongZhong
    Chen, FeiHeng
    Tao, HongFang
    Zheng, ZhengJin
    Lin, Wuqiang
    Chen, Xiuli
    Meng, Meili
    Yu, Lian
    Chen, LongTian
    Huang, JianQing
    Wu, Guocai
    Zhao, Mengxia
    Liu, Zhenfang
    Zhu, Hongqian
    Jiang, Yirong
    Liu, Qifa
    Liu, Xiaoli
    Xu, Na
    BLOOD, 2023, 142
  • [22] The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine
    Doyel, Michael
    Bouligny, Ian Michael
    Murray, Graeme
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Thuy Ho
    Zacholski, Kyle
    Venn, Chad Michael
    Alnimer, Yanal Mufeed
    Wages, Nolan
    Grant, Steven
    Maher, Keri Renee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.
    Gu, Chengyuan
    Wang, Ruju
    Kang, Huizhu
    He, Xuefeng
    Chen, Jun
    Lin, Zhihong
    Liu, Yuejun
    Yang, Ting
    Wu, Depei
    Han, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
    Liu, Qingyang
    Yang, Jingjing
    Lv, Lei
    Zhang, Xiawei
    Li, Meng
    Xu, Lingmin
    Huang, Sai
    Jing, Yu
    Dou, Liping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [25] Efficacy and Safety of Homoharringtonine for the Treatment of Acute Myeloid Leukemia: A Meta-analysis
    Mi, Ruihua
    Zhao, Jin
    Chen, Lin
    Wei, Xudong
    Liu, Jia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : E752 - E767
  • [26] Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study
    Guangyang Weng
    Jingya Huang
    Xin He
    Tingting Xue
    Linlin Yang
    Yu Zhang
    Guopan Yu
    Zhiqiang Sun
    Dongjun Lin
    Lan Deng
    Xinquan Liang
    Jie Xiao
    Hongyu Zhang
    Ziwen Guo
    Hua Jin
    Qifa Liu
    Xin Du
    Annals of Hematology, 2023, 102 : 3369 - 3381
  • [27] Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study
    Weng, Guangyang
    Huang, Jingya
    He, Xin
    Xue, Tingting
    Yang, Linlin
    Zhang, Yu
    Yu, Guopan
    Sun, Zhiqiang
    Lin, Dongjun
    Deng, Lan
    Liang, Xinquan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Jin, Hua
    Liu, Qifa
    Du, Xin
    ANNALS OF HEMATOLOGY, 2023, 102 (12) : 3369 - 3381
  • [28] Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia
    Zhou, Zepin
    Zhao, Xingli
    Suo, Xiaohui
    Bai, Guanchen
    Shi, Zeyan
    Luo, Yunya
    Tan, Yaxian
    Lu, Xinxiao
    Yuan, Linyu
    Zhang, Congcong
    Li, Yinling
    Gao, Sifeng
    Zhang, Jilei
    Li, Heng
    Zhao, Weihua
    Peng, Hongling
    Guo, Pengxiang
    Mi, Yingchang
    Liu, Kaiqi
    BLOOD, 2023, 142
  • [29] Efficacy and safety of venetoclax and azacytidine for acute myeloid leukemia: a retrospective, single-center study
    Yamaguchi, Y.
    Hirano, D.
    Minami, R.
    Hirano, S.
    Suzuki, Y.
    Imahashi, N.
    Adachi, T.
    Nagai, H.
    Iida, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1333 - S1333
  • [30] Venetoclax Added to Cladribine (CLAD) plus Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
    Reville, Patrick K.
    Kantarjian, Hagop
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    DiNardo, Courtney D.
    Sasaki, Koji
    Short, Nicholas
    Issa, Ghayas C.
    Ohanian, Maro
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Maiti, Abhishek
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N.
    Takahashi, Koichi
    Rausch, Caitlin R.
    Hammond, Danielle
    Malla, Rashmi
    Quagliato, Kelly
    Brandt, Mark
    Popat, Uday R.
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2022, 140 : 9041 - 9043
12345